Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis

Ying Ying Leung; William Tillett; Pil Hojgaard; Ana-Maria Orbai; Richard Holland; Ashish J Mathew; Niti Goel; Jeffrey Chau; Christine A Lindsay; Alexis Ogdie; Laura C Coates; Robin Christensen; Philip J Mease; Vibeke Strand; Dafna D Gladman

doi:10.3899/jrheum.210175

Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis

J Rheumatol. 2021 Oct;48(10):1547-1551. doi: 10.3899/jrheum.210175. Epub 2021 Apr 15.

Authors

Affiliations

¹ Y.Y. Leung, MB ChB, MD, Singapore General Hospital, and Duke-NUS Medical School, Singapore; katyccc@hotmail.com.
² W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK.
³ P. Hojgaard, MD, PhD, Department of Rheumatology, Holbæk Hospital, Holbæk, and Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
⁴ A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁵ R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia.
⁶ A.J. Mathew, MBBS, DNB, DM, The Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Disorders, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark, and Centre for Prognosis Studies in Rheumatic Diseases, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada, and Department of Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India.
⁷ N. Goel, MD, Patient Research Partner, Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA.
⁸ J. Chau, BA, MCS, Patient Research Partner, Hong Kong.
⁹ C.A. Lindsay, PharmD, Patient Research Partner, employed by Aurinia Pharma US Inc., Prosper, Texas, USA.
¹⁰ A. Ogdie, MD, MSCE, Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹¹ L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
¹² R. Christensen, BSc, MSc, PhD, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.
¹³ P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA.
¹⁴ V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA.
¹⁵ D.D. Gladman, MD, FRCPC, Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.

Abstract

Objective: Due to no existing data, we aimed to derive evidence to support test-retest reliability for the Health Assessment Questionnaire-Disability Index (HAQ-DI) and 36-item Short Form Health Survey physical functioning domain (SF-36 PF) in psoriatic arthritis (PsA).

Methods: We identified datasets that collected relevant data for test-retest reliability for HAQ-DI and SF-36 PF, and evaluated them using Outcome Measures in Rheumatology (OMERACT) Filter 2.1 methodology. We calculated intraclass correlation coefficients (ICC) as a measure of test-retest reliability. We then conducted a quality assessment and evaluated the adequacy of test-retest reliability performance.

Results: Two datasets were identified for HAQ-DI and 1 for SF-36 PF in PsA. The quality of the datasets was good. The ICCs for HAQ-DI were good and excellent in study 1 (0.90, 95% CI 0.79-0.95) and study 2 (0.94, 95% CI 0.89-0.97). The ICC for SF-36 PF was excellent (0.96, 95% CI 0.92-0.98). The performance of test-retest reliability for both instruments was judged to be adequate.

Conclusion: The new data derived support good and reasonable test-retest reliability for HAQ-DI and SF-36 PF in PsA.

Keywords: patient-reported outcome; physical function; psoriatic arthritis; test-retest reliability.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Arthritis, Psoriatic* / diagnosis
Disability Evaluation
Humans
Reproducibility of Results
Surveys and Questionnaires

Abstract

Publication types

MeSH terms

Grants and funding